BEAM — Beam Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1745999 ·
Last close
$24.23
Market Cap
$2.50B
52W High
$38.26
52W Low
$20.23
ADV30
1,903,951
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 490,000 | — | -126,553,000 | -122,678,000 | 1,386,355,000 | 219,825,000 | 318,913,000 |
| Mar 2026 | 31,738,000 | — | -107,215,000 | -94,318,000 | 1,480,798,000 | 288,291,000 | 316,360,000 |
| Dec 2025 | 114,109,000 | — | -17,445,000 | 244,297,000 | 1,481,177,000 | 294,944,000 | 242,819,000 |
| Sep 2025 | 9,698,000 | — | -126,811,000 | -112,728,000 | 1,311,081,000 | 267,960,000 | 345,079,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-359,377,000
Investing CF
$189,456,000
Financing CF
$107,692,000
CapEx
$-13,391,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.86
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,858,215,000
Inventory
—
Receivables
—
ST Investments
$933,102,000
EBIT TTM
$-378,024,000
Pretax Income TTM
$-85,882,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$156,035,008
EBITDA
$-355,780,992
Free Cash Flow
$-241,844,000
Enterprise Value
$1,491,648,512
Total Cash
$1,152,926,976
Total Debt
$247,358,000
Shares Out
103,287,665
Trailing EPS
$-0.69
Book Value
$10.69
ROE
-8.2%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 139,743,000 | -383,693,000 | -79,992,000 | 1,481,177,000 | 242,819,000 | 1,238,358,000 | -345,102,000 |
| Dec 2024 | 63,518,000 | -415,568,000 | -376,742,000 | 1,103,824,000 | 370,279,000 | 733,545,000 | -347,246,000 |
| Dec 2023 | 377,709,000 | -176,485,000 | -132,527,000 | 1,459,714,000 | 478,385,000 | 981,329,000 | -149,195,000 |
| Dec 2022 | 60,920,000 | -338,479,000 | -289,088,000 | 1,341,714,000 | 608,240,000 | 733,474,000 | 22,527,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.74
Max Pain — expiry 2028-01-21
max pain strike: $30.00 · spot: $24.23 · call oi: 4,009 · put oi: 1,017
Expected Move to 2028-01-21:
±$14.72
(60.75%) —
implied range
$9.51 –
$38.95
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $2.47B | $1.90 | — |
| ADMA | ADMA BIOLOGICS, INC. | $2.27B | $10.12 | — |
| ALVO | Alvotech | $2.19B | $6.15 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.16B | $8.47 | — |
| VCEL | Vericel Corp | $2.06B | $40.24 | — |
News headlines (Yahoo Finance, 1h cache)
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
2026-09-28 21:02 · Yahoo
Anthropic AI Discovery Gene-Editing Stocks Falling
2026-09-24 12:46 · Yahoo
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
2026-09-24 01:14 · Yahoo
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-22 11:10 · Yahoo
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?
2026-09-10 23:33 · Yahoo
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
2026-09-08 13:22 · Yahoo
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
2026-09-01 11:00 · Yahoo
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
2026-08-31 11:00 · Yahoo
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
2026-09-18 15:38 · Yahoo
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
2026-09-17 20:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.